BAM15

At A Glance

The list of absolute contraindications to BAM15 is long precisely because the compound is uncharacterized in humans, and in the absence of data most physiologic conditions that could plausibly interact badly with mitochondrial uncoupling are presumed contraindications. Anyone with known or suspected heart disease should not use BAM15 — protonophore-induced increases in heart rate and cardiac metabolic demand are theoretically dangerous in the setting of coronary artery disease, heart failure, arrhythmias, cardiomyopathy, or structural heart disease. This includes patients with a history of myocardial infarction, stent placement, coronary artery bypass grafting, congenital heart disease, or implanted cardiac devices (pacemaker, ICD). Anyone with hyperthyroidism or untreated thyroid nodules should not use BAM15 because the metabolic profile overlaps with thyroid excess and the combination amplifies cardiovascular and thermoregulatory risk. Patients on thyroid hormone replacement (levothyroxine, liothyronine) are a related contraindication because the dose of thyroid hormone is titrated to a specific metabolic setpoint and adding an uncoupler disturbs that setpoint in ways that are hard to anticipate. Anyone with hepatic impairment — active hepatitis, cirrhosis, significant fatty liver with elevated enzymes, or prior drug-induced liver injury — should avoid BAM15 because hepatic metabolism of the compound is uncharacterized and liver stress from mitochondrial dysfunction is theoretically additive to pre-existing liver pathology. Anyone with renal impairment should avoid BAM15 because uncoupler-induced increases in metabolic rate and fluid losses can precipitate renal dysfunction, and drug elimination pathways are not characterized. Pregnancy and breastfeeding are absolute contraindications — no reproductive toxicology data exist in humans, and the rodent data for DNP suggest uncouplers in general are teratogenic and should not be used during gestation. Anyone trying to conceive, male or female, should avoid BAM15 because reproductive effects are unknown and the cost of caution is low. Children and adolescents should not use BAM15 under any circumstances; the compound has not been studied in developmental age groups and the metabolic effects are not appropriate for anyone whose growth and maturation is ongoing. Anyone with a history of heat-related illness — heat stroke, heat exhaustion, malignant hyperthermia, neuroleptic malignant syndrome, serotonin syndrome — should absolutely avoid uncouplers because baseline thermoregulatory vulnerability is amplified by the mechanism. Anyone with seizure disorders should avoid BAM15 because thermogenesis, electrolyte shifts, and cellular energy stress are seizure triggers in susceptible individuals. Anyone with a history of rhabdomyolysis, statin-induced myopathy, or mitochondrial myopathy should avoid BAM15 because muscle tissue is particularly vulnerable to uncoupler-induced ATP stress. Anyone with eating disorders — anorexia nervosa, bulimia nervosa, binge eating disorder, body dysmorphia — should not use any compound that increases metabolic rate, because the underlying disorder is likely to drive inappropriate use and the compound will compound medical complications. Relative contraindications that warrant physician involvement if dosing is being considered at all include: type 1 diabetes (glucose management becomes more difficult with altered substrate utilization); type 2 diabetes on insulin (hypoglycemia risk); adrenal insufficiency; inflammatory bowel disease; autoimmune disease requiring immunomodulatory therapy; significant mental health conditions where medications might interact; and concurrent use of any metabolic pharmacology including GLP-1 agonists, SGLT2 inhibitors, metformin at doses above 1500 mg/day, bupropion, phentermine, topiramate, or naltrexone. Medications that interact pharmacokinetically with BAM15 are largely uncharacterized because no drug-drug interaction studies exist. Theoretical interactions include: anything that shares hepatic metabolism pathways (CYP3A4 substrates most likely); anything that increases sympathetic tone (amphetamines, caffeine at high intake, nicotine, decongestants); anything that increases core temperature (MAO inhibitors, SSRIs with serotonin syndrome potential, anticholinergics that impair sweating, antipsychotics); and anything that impairs renal or hepatic clearance. The correct framing is that BAM15 has been studied in rodents and not in humans, and any patient on any prescription medication should assume interactions are possible and discuss the situation with a physician — preferably one with expertise in clinical pharmacology rather than one being asked to rubber-stamp a decision already made. The final contraindication, which is the most important one, is the lack of a clinically overseen dosing and monitoring environment. If you do not have a physician who knows you are taking BAM15, who has access to your complete medical history, who can order appropriate labs and adjust or stop dosing based on findings, and who can evaluate you urgently if adverse effects develop, then you do not have the minimum supportive infrastructure for safe self-experimentation with this compound. That is not a contraindication because of any specific medical condition; it is a contraindication because uncoupler toxicity is not safely managed by an untrained person working alone, and the first adverse event is a worse time to build clinical infrastructure than the day before dosing began.

Molecular Weight

357.35 g/mol

CAS Number

203203-79-6

Trial Phase

Preclinical